Drug Discovery Industry Analysis
In this section you will find information products, including market research reports, on the following sector: Drug Discovery
RSS
previous
| Dermatological Drugs: World Market Prospects (VIS00294) 2013-2023Your guide to revenue prospects for the treatment of skin diseases What's the commercial outlook for treating skin disorders? Visiongain's updated report gives you forecasted revenues to 2023 and also explains... | Mar 2013 | £1,699€2,012$2,645 |
| PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022 (GDA37460) PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022 (GDA37385) PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022 (GDA37386) PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022 (GDA37384) PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022 (GDA37387) PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022 (GDA37388) PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022 (GDA37383) PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022 (GDA37459) PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022 (GDA37389) PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022'. Despite its... | Feb 2013 | £3,210€3,802$4,995 |
| Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market (CRI00267) 2013-2017Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and... | Feb 2013 | £1,155€1,368$1,800 |
| Oncology Drug Pipeline Update (Premium) - Online (BSK00572) With the Oncology Drug Pipeline Update (Premium) you will have online access to competitive drug information for almost 6,000 drugs across 120 indications in oncology via our intuitive guided searches,... | Feb 2013 | £0 |
| Research Report on China's Anti-Alzheimer's Disease (AD) Drug Market (CRI00268) 2013-2017By the end of 2011, people aged 60 and above reached 185 million in China, accounting for 13.7% of the population, with an increase of 0.47 percentage point compared with... | Jan 2013 | £1,800€2,132$2,800 |
| Global Endocrinology Drugs Market (INF02227) 2012-2016TechNavio's analysts forecast the Global Endocrinology Drugs market to grow at a CAGR of 7.58 percent over the period 2012-2016. One of the key factors contributing to this market growth... | Jan 2013 | £1,285€1,522$2,000 |
| Oncology Drug Pathway Analyzer (Premium Version) (BSK00566) New for 2013: Free online updates for a year Get instant, interactive pathway modeling on almost 3,000 cancer drugs across close to 90 different cancer types. Drug targets and their pathways... | Jan 2013 | £0 |
| Oncology Drug Pathway Analyzer (Standard Version) (BSK00565) New for 2013: Free online updates for a year Get instant, interactive pathway modeling on almost 3,000 cancer drugs across close to 90 different cancer types. Drug targets and their... | Jan 2013 | £0 |
| China Heparin Industry Report (RIC00620) 2012-2014China, abundant in heparin raw materials, has become one of the world's largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually.... | Dec 2012 | £1,285€1,522$2,000 |
| Drug Discovery Outsourcing (VIS00306) World Market 2013-2023Report Details How much revenue can drug discovery outsourcing generate? Our new report shows you See what the future holds for outsourcing early-stage drug development. There is rising demand for those services.... | Nov 2012 | £1,549€1,835$2,411 |
| CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, Apf530 & Rolapitant) - Global Market Opportunity Assessment Study (TAN00140) 2012 - 2018Description This report is an effort to identify factors, which will be the driving force behind the market penetration and corresponding sales of the pipeline chemotherapy-induced nausea and vomiting (CINV) drugs,... | Nov 2012 | £2,950€3,494$4,595 |
| Thin Film Drug Manufacturing in the US (IBI04055) IBISWorld Industry ReportThin Film Drug ManufacturingThin film drug manufacturers have experienced rapid revenue growth over the past five years, and this trend is expected to continue over the next five as the... | Nov 2012 | £595€705$925 |
| Research Report on China's Hypolipidemic Drug Market (CRI00176) 2012-2013As the population further aging in China, the proportion of diseases such as hypertension caused by hyperlipidemia in cardiovascular diseases of the elderly presents an increasing trend year by year... | Nov 2012 | £1,540€1,824$2,400 |
| Global Heparin Market (INF02034) 2011-2015TechNavio's analysts forecast the Global Heparin market to grow at a CAGR of 11.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is... | Nov 2012 | £965€1,143$1,500 |
| Global Membrane Separation Market (INF02061) 2011-2015TechNavio's analysts forecast the Global Membrane Separation market to grow at a CAGR of 8.78 percent CAGR over the period 2011-2015. One of the key factors contributing to this market... | Nov 2012 | £965€1,143$1,500 |
| Biomarkers in Drug Discovery (GBI00025) Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic OutcomesBiomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes Summary GBI Research's new report, "Biomarkers in Drug Discovery - Integration in Early Stage... | Nov 2012 | £2,250€2,665$3,500 |
| Active Pharmaceutical Ingredients (APIs) Market in Asia Pacific to 2017 (GBI00479) Increasing Penetration in China and India Coupled with Low Cost Manufacturing to Fuel Regional GrowthActive Pharmaceutical Ingredients (APIs) Market in Asia Pacific to 2017 - Increasing Penetration in China and India Coupled with Low Cost Manufacturing to Fuel Regional Growth Summary GBI Research's report, "Active Pharmaceutical... | Nov 2012 | £2,250€2,665$3,500 |
